Ignite Creation Date:
2025-12-24 @ 5:49 PM
Ignite Modification Date:
2025-12-29 @ 2:44 PM
Study NCT ID:
NCT00373568
Status:
COMPLETED
Last Update Posted:
2010-06-02
First Post:
2006-09-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis
Sponsor:
AB Foundation
Organization:
Study Overview
Official Title:
Miltefosine (42 Days) for Mucosal Leishmaniasisi
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis
Detailed Description:
Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: